

David T Yang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6935411/publications.pdf>

Version: 2024-02-01

41
papers

1,524
citations

489802

18
h-index

406436

35
g-index

42
all docs

42
docs citations

42
times ranked

5351
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>Asxl1</i> loss cooperates with oncogenic <i>Nras</i> in mice to reprogram the immune microenvironment and drive leukemic transformation. <i>Blood</i> , 2022, 139, 1066-1079.	0.6	24
2	EGR1 Addiction in Diffuse Large B-cell Lymphoma. <i>Molecular Cancer Research</i> , 2021, 19, 1258-1269.	1.5	6
3	Autoimmune Lymphoproliferative Syndrome: An Overview. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 245-251.	1.2	39
4	Utilization and Results of Repeat SARS-CoV-2 RT-PCR Testing in a Presumptive Low Prevalence Population. <i>Wisconsin Medical Journal</i> , 2020, 119, 177-181.	0.3	0
5	PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells. <i>Leukemia</i> , 2019, 33, 2898-2911.	3.3	41
6	Metabolic Rewiring in Response to Biguanides Is Mediated by mROS/HIF-1a in Malignant Lymphocytes. <i>Cell Reports</i> , 2019, 29, 3009-3018.e4.	2.9	34
7	Downregulating Notch counteracts KrasG12D-induced ERK activation and oxidative phosphorylation in myeloproliferative neoplasm. <i>Leukemia</i> , 2019, 33, 671-685.	3.3	12
8	Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 95-102.	0.2	9
9	VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e61-e67.	0.2	13
10	Unique dependence on <i>Sos1</i> in KrasG12D-induced leukemogenesis. <i>Blood</i> , 2018, 132, 2575-2579.	0.6	23
11	NR4A1 inhibition synergizes with ibrutinib in killing mantle cell lymphoma cells. <i>Blood Cancer Journal</i> , 2017, 7, 632.	2.8	3
12	Clonality and mutational profiling of a case of composite hairy cell leukemia and chronic lymphocytic leukemia. <i>Journal of Hematopathology</i> , 2017, 10, 81-86.	0.2	3
13	Pegivirus avoids immune recognition but does not attenuate acute-phase disease in a macaque model of HIV infection. <i>PLoS Pathogens</i> , 2017, 13, e1006692.	2.1	15
14	Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma. <i>Cancer</i> , 2016, 122, 559-564.	2.0	67
15	Mechanism governing heme synthesis reveals a GATA factor/heme circuit that controls differentiation. <i>EMBO Reports</i> , 2016, 17, 249-265.	2.0	55
16	Follicular lymphoma: evolving therapeutic strategies. <i>Blood</i> , 2016, 127, 2055-2063.	0.6	142
17	Sole rearrangement but not amplification of <i>MYC</i> is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable. <i>British Journal of Haematology</i> , 2016, 175, 631-640.	1.2	55
18	Loss of SIRT3 Provides Growth Advantage for B Cell Malignancies. <i>Journal of Biological Chemistry</i> , 2016, 291, 3268-3279.	1.6	75

#	ARTICLE	IF	CITATIONS
19	Exosome complex orchestrates developmental signaling to balance proliferation and differentiation during erythropoiesis. <i>ELife</i> , 2016, 5, .	2.8	32
20	Orchestrating Developmental Signaling to Balance Erythroblast Proliferation and Differentiation. <i>Blood</i> , 2016, 128, 699-699.	0.6	1
21	Discovery of survival factor for primitive chronic myeloid leukemia cells using induced pluripotent stem cells. <i>Stem Cell Research</i> , 2015, 15, 678-693.	0.3	33
22	A unique CD4+ large granular lymphocytosis occurring in patients treated with tumor necrosis factor β inhibitors: report of 2 cases. <i>Human Pathology</i> , 2015, 46, 1237-1241.	1.1	8
23	Functional and Histological Evaluation following Canine Vocal Fold Reconstruction Using Composite Thyroid Ala Perichondrium Flaps. <i>Otolaryngology - Head and Neck Surgery</i> , 2015, 153, 79-87.	1.1	3
24	AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 2601-2612.	3.2	94
25	TPL2 kinase regulates the inflammatory milieu of the myeloma niche. <i>Blood</i> , 2014, 123, 3305-3315.	0.6	89
26	The exosome complex establishes a barricade to erythroid maturation. <i>Blood</i> , 2014, 124, 2285-2297.	0.6	58
27	Pure Erythroid Leukemia Presenting in a HIV-Positive Patient. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e35-e38.	0.2	4
28	Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). <i>Blood</i> , 2014, 123, 1665-1673.	0.6	61
29	Hematoidin. <i>Blood</i> , 2014, 124, 2158-2158.	0.6	6
30	Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. <i>Blood</i> , 2014, 124, 2354-2361.	0.6	382
31	The RNA-Degrading Exosome Complex Is an Endogenous Suppressor of Erythroid Maturation. <i>Blood</i> , 2014, 124, 2659-2659.	0.6	0
32	Induced Pluripotent Stem Cell Model of Chronic Myeloid Leukemia Revealed Olfactomedin 4 As a Novel Survival Factor for Primitive Leukemia Cells. <i>Blood</i> , 2014, 124, 397-397.	0.6	1
33	In Vitro Epithelial Differentiation of Human Induced Pluripotent Stem Cells for Vocal Fold Tissue Engineering. <i>Annals of Otology, Rhinology and Laryngology</i> , 2013, 122, 737-747.	0.6	15
34	Mature Results From ECOG Study E1405 – A Phase II Study of VcR-CVAD with Maintenance Rituximab for Previously Untreated Mantle Cell Lymphoma. <i>Blood</i> , 2012, 120, 153-153.	0.6	9
35	SOX11 Directly Represses Wnt/ β -Catenin Signaling and Identifies a Subgroup of Mantle Cell Lymphoma Patients with Improved Survival with Intensive Treatment. <i>Blood</i> , 2012, 120, 895-895.	0.6	2
36	Use of Tissue Microarray and Automated Quantitative Analysis for Screening and Validation of Potential Biomarkers in Mantle Cell Lymphoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2011, 19, 62-69.	0.6	6

#	ARTICLE	IF	CITATIONS
37	VcRâ€CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. British Journal of Haematology, 2011, 155, 190-197.	1.2	48
38	High-Resolution Chromatin Immunoprecipitation (ChIP) Sequencing Identifies Novel Binding Targets and Prognostic Role for SOX11 in Mantle Cell Lymphoma. Blood, 2011, 118, 585-585.	0.6	0
39	Identification of Potential Prognostic Biomarkers in Mantle Cell Lymphoma by Array-Based Quantitative Nuclease Protection Assay. Blood, 2010, 116, 2007-2007.	0.6	0
40	Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. Molecular Cancer, 2008, 7, 40.	7.9	56
41	The Critical Role of IÎ±bÎ± Dependent Nuclear Export of NF-Î±b in B-Cell Development.. Blood, 2008, 112, 1533-1533.	0.6	0